BillionToOne, Inc. filings document the regulatory record for a public molecular diagnostics company commercializing QCT-based prenatal and oncology testing. Recent Form 8-K disclosures furnish operating results, financial guidance, Regulation FD presentation materials and executive compensation arrangements, including the company’s annual incentive plan and equity-based payment provisions.
Proxy materials describe annual meeting mechanics, stockholder voting matters, board governance and related governance disclosures. Together, the filings address the company’s clinical testing revenue categories, Class A common stock compensation framework, furnished earnings materials and governance matters relevant to its Nasdaq-listed operating-company status.
BillionToOne, Inc. (BLLN) SVP of Laboratory Operations John Roderick ten Bosch sold 1,416 shares of Class A Common Stock at $106.61 per share on September 21, 2026. He directly held 23,635 shares after the sale. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by him on June 2, 2026.
BillionToOne, Inc. (BLLN) insider Thomas P. Lynch, the company’s General Counsel, Chief Compliance Officer and Secretary, reported option exercises and related share sales in Class A Common Stock on September 17, 2026. He exercised stock options covering 35,112 shares at exercise prices from $8.65 to $30.78 per share, receiving the same number of Class A shares. He then sold 35,112 shares of Class A Common Stock in multiple open-market or private transactions at weighted average prices around $110 per share, with sale-price ranges detailed in the footnotes. All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on June 8, 2026, and the options exercised were fully vested and exercisable.
BillionToOne, Inc. (BLLN) officer John Roderick ten Bosch has filed a notice of proposed sale of 1,416 Class A shares of BillionToOne common stock through Fidelity Brokerage Services LLC, with an estimated aggregate sale price of $150,959.76, to be sold on or after September 21, 2026 on NASDAQ.
The filing also lists prior sales of Class A shares by John R. Ten Bosch during the past three months, including separate transactions of 1,416, 4,251, 1,417, 1,417, and 1,416 shares, each with stated dollar amounts received.
BillionToOne, Inc. (BLLN) has a notice of proposed sale under Rule 144 filed for officer Thomas P. Lynch. The notice covers the potential sale of 35,112 Class A shares, expected around September 17, 2026, through Fidelity Brokerage Services LLC, in connection with a stock option exercise for cash. The filing states an aggregate market value of $3,873,965.78 for these shares and notes that 42,644,388 Class A shares were outstanding, which is a baseline figure, not the amount being sold. Over the prior three months, Lynch sold 20,000 Class A shares on September 8, 2026 for $1,999,879.96.
BillionToOne, Inc. (BLLN) reports that Chairman and CEO Atay Oguzhan exercised stock options covering 24,999 shares of Class A Common Stock at an exercise price of $2.80 per share on September 14, 2026, and that he sold 30,331 shares of Class A Common Stock in multiple transactions that day.
The company states that these sales, including sales of shares held by his spouse, occurred at weighted average prices generally between $98.060 and $101.820 per share, were effected in open-market transactions pursuant to Rule 10b5-1 trading plans adopted on June 5, 2026 and June 7, 2026, and involved fully vested stock options expiring on June 7, 2031.
BillionToOne, Inc. (BLLN) reported that Chief Product Officer Shan Riku Sakakibara made a bona fide gift transfer of 3,500 shares of Class A Common Stock on September 10, 2026. No price was paid for the gift, and Sakakibara now holds 196,500 shares directly. No Rule 10b5-1 trading plan is reported.
BillionToOne, Inc. (BLLN) is the issuer for a Rule 144 notice filed for the account of Oguzhan Atay covering potential sales of up to 24,999 Class A shares of common stock. The shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ, in connection with a stock option exercise dated September 14, 2026.
The notice also reports that, within the prior three months, related accounts sold multiple blocks of BillionToOne Class A shares, including 26,250 shares by Oguzhan Atay on July 6, 2026, 32,500 shares by him on August 3, 2026, and 15,539 shares on August 5, 2026, as well as sales by his spouse and the Atay 2021 Dynasty Trust. Reported outstanding Class A shares total 42,644,388 as of September 14, 2026.
BillionToOne, Inc. (BLLN) has a Form 144 notice indicating that securities beneficially associated with officer and director Oguzhan Atay are being proposed for sale under Rule 144. The notice covers the potential sale of 5,332 Class A shares of pre-IPO stock through Fidelity Brokerage Services LLC and lists prior sales in the last three months by his spouse and the Atay 2021 Dynasty Trust.
BillionToOne, Inc. (BLLN) reported that John Roderick ten Bosch, its SVP of Laboratory Operations, sold 1,416 shares$97.54 per share25,051 shares
The filing states that this transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 2, 2026
BillionToOne, Inc. (BLLN) reported that Chief Technology Officer David Tsao exercised options to acquire 20,000 shares of Class A Common Stock at an exercise price of $2.80 per share on September 9, 2026, and sold 20,000 shares the same day in two transactions at $97.54 and $100.00 per share. These transactions were carried out under a Rule 10b5-1 trading plan adopted on June 5, 2026, and the options exercised were fully vested and exercisable.